-Mr. Barrow previously served as interim Chief Executive
Officer and Chief Development Officer of MindMed
-Carol Vallone appointed as
Chair of the Board of Directors, Andreas
Krebs appointed as Vice Chair and Perry Dellelce transitions from his role as
Chairman-
NEW YORK, Dec. 14, 2021 /CNW/ -- Mind Medicine (MindMed)
Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a
leading biotech company developing psychedelic-inspired therapies,
today announced that Robert Barrow
was appointed as Chief Executive Officer and as a member of the
Board of Directors, effective immediately. Mr. Barrow previously
served as interim Chief Executive Officer and Chief Development
Officer of MindMed and brings strategic expertise and deep industry
insight to his role.
![Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed)) Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed))](https://mma.prnewswire.com/media/996320/Mindmed_Logo.jpg)
Mr. Barrow commented, "I am delighted to join MindMed's Board of
Directors and look forward to building on the progress to date
alongside our outstanding executive leadership team, all while
advancing the Company into the future. This is an exciting time for
MindMed, and my immediate priority will be to leverage the
necessary resources to advance our clinical development programs.
In parallel, our team will continue to explore new opportunities
that expand MindMed's pipeline—bringing forward novel therapies and
executing on our mission to deliver on the therapeutic potential of
psychedelics for the many patients in need."
Mr. Perry Dellelce has stepped
down from his role as Director and Chairman of the Company's Board
of Directors, effective immediately. With the departure of Mr.
Dellelce, the Board has appointed Ms. Carol
Vallone to serve as Chair of the Board of Directors and Mr.
Andreas Krebs to serve as Vice
Chair.
Mr. Dellelce added, "It has been a tremendous honor to serve on
MindMed's Board of Directors, and I am incredibly proud of
everything our team has accomplished. Rob, Carol and Andreas'
diverse backgrounds across the biotech and healthcare industries
will be invaluable as MindMed continues its efforts to transform
mental health treatment. I have the greatest confidence in the
leadership team's ability to maximize the value of our platform and
successfully lead MindMed through this next phase of continued
growth."
Ms. Vallone added, "Since MindMed's inception, Perry has played
a pivotal role in the Company's evolution to become a leader in the
psychedelic sector. I, along with the entire Board and executive
team, wish to formally acknowledge and thank him for his guidance,
vision and significant contributions. As we enter this inflection
point and execute on our path forward, we are thrilled to name Rob
as our permanent CEO, whose strategic agility, strong leadership
and impressive track record makes him exceptionally well
qualified."
Robert Barrow is an
accomplished pharmaceutical executive with over a decade of
experience leading organizations and drug development programs in a
variety of disease areas. Mr. Barrow is a recognized leader in the
psychedelic industry, in which he has played a central role in the
design and execution of several successful regulatory and drug
development strategies. Mr. Barrow previously served as the
head of drug development & discovery at Usona Institute, where
he led research and development efforts for Usona's psychedelic
drug candidates and was responsible for obtaining Breakthrough
Therapy Designation for psilocybin in the treatment of Major
Depressive Disorder. Prior to his tenure at Usona, Mr. Barrow
served as Chief Operating Officer and a Director of Olatec
Therapeutics, where he oversaw the execution of numerous early and
late-stage clinical trials in the fields of analgesics,
rheumatology, immunology and cardiovascular disease. Mr. Barrow has
also served as a technical and strategic advisor to numerous large
and small pharmaceutical companies developing novel central nervous
system therapeutics and has been an invited speaker at multiple
industry and scientific presentations. Mr. Barrow holds a M.S. in
Pharmacology from The Ohio State
University and a B.S. from Wake Forest
University, where he graduated summa cum laude.
Carol Vallone is an
esteemed executive and corporate board director, with a strong
track record in launching, scaling and selling global companies.
Currently, she serves as Board Director, Chair of Compensation
Committee, and Member of Audit/Finance Committee at MindMed. She
also serves as Chair of the Board of Trustees at McLean Hospital,
the #1 ranked freestanding psychiatric hospital and largest
psychiatric affiliate of Harvard Medical
School, as well as the board of trustees at MGH Institute of
Health Professions and on the finance committee at Mass General
Brigham. Additionally, Ms. Vallone serves as a board member for the
publicly traded Cresco Labs, and for a Bain Capital Double Impact
portfolio company, Arosa. She is also an Advisory Director for the
investment firm, Berkshire Partners, and an Advisory Board Member
of the healthcare-focused venture growth firm, Longitude Capital.
In addition, Ms. Vallone has served as founder & CEO of global
e-learning companies, held management positions in leading
corporate technology companies and served on the boards of a public
financial services and private e-commerce organization.
Andreas Krebs is an
internationally experienced executive, entrepreneur and
best-selling author ("The Illusion of Invincibility"). He heads the
family-owned investment company Longfield Invest
(Langenfeld/Germany), which
focuses on growth companies in various industries as well as in the
new economy. He has worked in seven countries, in Latin
America, Asia and Canada and as President and
Executive Board Member of Wyeth Corporation in the
United States. Andreas Krebs was Chairman of the Supervisory
Board and Shareholder Council of Merz
Pharma, Frankfurt am Main, Germany from 2010 to
2019, is currently a member of the Supervisory Board of the
European eye clinic group Veonet (Nordic Capital Group) and
holds other board positions across various
sectors. Furthermore, he serves as Chairman of the private
non-governmental organization, Förderverein Girassol eV, which
supports children and young people from socially difficult
backgrounds in São Paulo, Brazil.
About MindMed
MindMed is a clinical-stage psychedelic
medicine biotech company that seeks to discover, develop and deploy
psychedelic-inspired medicines and therapies to address addiction
and mental illness. The Company is assembling a compelling drug
development pipeline of innovative treatments based on psychedelic
substances including psilocybin, LSD, MDMA, DMT and an ibogaine
derivative, 18-MC. The MindMed executive team brings extensive
biopharmaceutical experience to MindMed's approach to developing
the next generation of psychedelic-inspired medicines and
therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute "forward-looking information" within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "will", "may", "should", "could",
"intend", "estimate", "plan", "anticipate", "expect", "believe",
"potential" or "continue", or the negative thereof or similar
variations. Forward-looking information in this news release
include, but are not limited to, statements regarding the ability
to execute on our business strategy, expand our pipeline and
achieve growth. Although the Company believes that the
expectations reflected in such forward-looking information are
reasonable, such information involves risks and uncertainties, and
undue reliance should not be placed on such information, as unknown
or unpredictable factors could have material adverse effects on
future results, performance or achievements of the Company. There
are numerous risks and uncertainties that could cause actual
results and the Company's plans and objectives to differ materially
from those expressed in the forward-looking information, including
history of negative cash flows; limited operating history;
incurrence of future losses; availability of additional capital;
lack of product revenue; compliance with laws and regulations;
difficulty associated with research and development; risks
associated with clinical trials or studies; heightened regulatory
scrutiny; early stage product development; clinical trial risks;
regulatory approval processes; novelty of the psychedelic inspired
medicines industry; as well as those risk factors discussed or
referred to herein and the risks described under the headings "Risk
Factors" in the Company's filings with the securities regulatory
authorities in all provinces and territories of Canada which are available under the Company's
profile on SEDAR at www.sedar.com and with the U.S. Securities and
Exchange Commission on EDGAR at www.sec.gov. Should one or more of
these risks or uncertainties materialize, or should assumptions
underlying the forward-looking information prove incorrect, actual
results and future events could differ materially from those
anticipated in such information. Although the Company has attempted
to identify important risks, uncertainties and factors that could
cause actual results to differ materially, there may be others that
cause results not to be as anticipated, estimated or intended.
These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on
the dates they are made and are expressly qualified in their
entirety by this notice. Except as required by law, the Company
does not intend and does not assume any obligation to update this
forward-looking information.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-appoints-robert-barrow-as-chief-executive-officer-and-director-301443953.html
SOURCE Mind Medicine (MindMed) Inc.